SiteOne Therapeutics
Biotechnology company developing non-opioid pain therapeutics by targeting voltage-gated sodium channels, leveraging natural toxin-derived compounds to create safer and more effective pain treatments.
Notes
SiteOne Therapeutics is a biotechnology company developing non-opioid pain therapeutics by targeting voltage-gated sodium channels. The company is headquartered in Bozeman, Montana.
The company's approach is based on the discovery that certain natural toxins can selectively modulate sodium channel activity. SiteOne is developing these toxin-derived compounds into safe and effective pain treatments that work through a completely different mechanism than opioids, potentially avoiding the addiction and abuse liabilities associated with current pain medications.
The company is backed by Novo Holdings and is focused on addressing the significant unmet need for effective, non-addictive pain treatments.
Team
- Ken Bhardwaj, Ph.D. - Chief Executive Officer
- Frank Bhardwaj, Ph.D. - Co-founder
Additional Research Findings
- Investor: Novo Holdings
- Focus on non-opioid pain therapeutics
- Voltage-gated sodium channel targeting
- Natural toxin-derived compounds
- Bozeman, Montana headquarters
- Founded in 2014
- Addressing opioid crisis with alternative pain treatments
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Novo Holdings | Hellerup, Denmark | biotech-focused | seedseries-a+3 | 13 |